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To date, IL-21 stands out as the most inﬂuential cytokine for human B cell activation and
differentiation. Indeed, when compared to other important B cell tropic cytokines such as
IL-2, IL-4, IL-6 and IL-10, IL-21 is clearly the most potent in terms of its ability to inﬂuence
humoral immune responses in humans. IL-21 has wide reaching actions in determining
how B cells will respond to co-stimulation ranging from induction of cell death upon BCR
crosslinking to potent induction of class switch recombination and plasma cell differenti-
ation when CD40 molecules are co-engaged. Another crucial B cell factor, exempliﬁed in
recent clinical trials, is BAFF/BLys. BAFF plays a critical role in the survival of human B cells
and plasma blasts and inﬂuences B cell expansion and migration. Recent evidence has
shown that IL-21 and BAFF can work in concert to promote and perhaps maintain humoral
immunity in humans. Notably, BAFF has the unique ability to substitute for CD40L activities
in regard to IL-21-co-stimulation and differentiation of a speciﬁc B cell subpopulation located
in the human splenic marginal zone. However, and perhaps surprisingly, BAFF signals do
not have the capability to override IL-21-driven cell death events when BCR is engaged. In
stark contrast, anti-CD40 ligation of B cells co-activated with IL-21 and anti-IgM not only
reverses this aforementioned activation-induced cell death, but transforms this death sig-
nal into one that drives plasma cell differentiation. Here we will discuss these two critical
B cell factors, IL-21 and BAFF, and their distinct and complimentary effects on human B
cell responses.
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INTRODUCTION
Memory B cells are generated following antigen exposure and rep-
resent a population of cells capable of mounting a swift and robust
secondary response to antigen re-encounter. In the case of immu-
nization, memory B cells are critical for maintaining a protective
humoral response to pathogens and may persist for decades (Lan-
zavecchia and Sallusto, 2009). However, re-activation of memory
B cells with self-reactive potential can lead to the production of
autoantibodies and promote autoimmune disease. Understand-
ing the pathways that promote the activation, differentiation, and
maintenance of naïve and memory B cells is crucial for discerning
the mechanisms that underlie autoimmune disorders. This review
will highlight the unique and synergistic effects of IL-21 and BAFF
on various subsets of human B cells.
IL-21: A COMMON γ CHAIN CYTOKINE WITH PLEIOTROPIC
ACTIVITIES
IL-21 is a member of the common gamma chain (γc) receptor
cytokine family with signiﬁcant homology to IL-2, IL-4, and IL-
15 (Ozaki et al., 2000; Parrish-Novak et al., 2000). IL-21 was ﬁrst
identiﬁed as a factor produced by in vitro-activated human CD3+
T cells and was later shown to be produced by NK T cells and
CD4+ T cells (Parrish-Novak et al., 2000; Chtanova et al., 2004;
Rasheed et al., 2006; Coquet et al., 2007). While various human
CD4+ helper T cell subsets express IL-21 mRNA, including Th1
and Th17 cells, Tfh cells are the most abundant producers of IL-21
(Chtanova et al., 2004; Rasheed et al., 2006). We found that IL-21
is spontaneously produced by tonsillar T cells in the absence of
stimulation (Kuchen et al., 2007). Similar ﬁndings were reported
by Bryant et al. (2007) who identiﬁed the IL-21 producing cells as
CD4+ CXCR5+ Tfh cells.
IL-21 signals through a receptor complex consisting of its own
private receptor, the IL-21R, and the γc (Asao et al., 2001; Spol-
ski and Leonard, 2010). Engagement of the IL-21R/γc complex
leads to the activation of several signaling pathways including the
Jak/STAT, MAPK, and PI3K pathways (Habib et al., 2002; Davis
et al., 2007; others). IL-21R is expressed on a broad array of cell
types including B cells, T cells, NK cells, macrophages, and den-
dritic cells, as well as other hematopoietic and non-hematopoietic
cells such as ﬁbroblasts, keratinocytes, and intestinal epithelial
cells (Spolski and Leonard, 2008b). On B cell subsets, IL-21R is
expressed on resting naïve and germinal center (GC) B cells and
is upregulated following anti-CD40 activation of both naïve and
memory B cells (Good et al., 2006). IL-21 up-regulates expression
of its own receptor either alone or in combination with anti-CD40
(Ettinger et al., 2008b).
IL-21has been reported tomodulate various aspects of immune
function. IL-21 promotes CD4 T cell differentiation and expan-
sion, CD8 T cell and NK cell expansion, and cytolytic activity, as
well as inhibits dendritic cell maturation and antigen presentation
and also has a variety of other effects on both hematopoietic and
non-hematopoietic cells (Spolski and Leonard, 2008a). Perhaps
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one of the most striking activities of IL-21 is its ability to sculpt
the humoral immune response. Although much has been done in
various mouse systems to reveal the effect of IL-21 in murine B cell
biology, the following will focus exclusively on the role of IL-21 in
human B cell immuno-regulation.
CONTEXT DEPENDENT INFLUENCE OF IL-21 ON HUMAN B
CELL EXPANSION AND PLASMA CELL DIFFERENTIATION
The process by which a naïve or memory B cell is activated and dif-
ferentiated into an Ig secreting plasma cell involves a series of steps,
several of which have been shown to be regulated by IL-21. Initially
following activation, B cells are induced to divide and expand. IL-
21 promotes robust B cell expansion following CD40 engagement
on both naïve and memory B cells isolated from either cord blood
or peripheral blood whereas CD40 engagement alone results in
minimal proliferation (Parrish-Novak et al., 2000; Ettinger et al.,
2005). It has been demonstrated that human splenic and tonsillar
B cell subsets also proliferate extensively under these conditions
(Good et al., 2006; Ettinger et al., 2007, 2008b).
Following B cell expansion, the proper signals can induce B cells
to undergo class switch recombination (CSR), afﬁnity mature, and
differentiate into plasma cells. IL-21 plays a complex role in these
B cell fate decisions. In combination with CD40 ligation, IL-21
induces CSR,plasma cell differentiation, and Ig production fromB
cells isolated from various lymphoid compartments via the induc-
tion of activation-induced deaminase (AID), a required factor for
somatic hypermutation and CSR, and BLIMP-1, a transcriptional
repressor involved in plasma cell differentiation (Pene et al., 2004;
Ettinger et al., 2005; Bryant et al., 2007). IL-21 co-stimulation,
however, does not initiate somatic hypermutation in vitro despite
the induction of AID (Ettinger et al., 2005).
IL-21 has the unique ability to induce cord blood naïve B cells
to maximally differentiate into plasma cells by co-stimulation with
CD40 engagement (Ettinger et al., 2005; Bryant et al., 2007). No
other cytokine to date has this same potential, including the com-
bination of IL-2/IL-10 and anti-CD40 or IL-10 and CD40L which
has been shown to induce plasma cell differentiation of memory
splenic B cells (Ettinger et al., 2005; Bryant et al., 2007). Further-
more, as cord blood B cells are exquisitely sensitive to death by
BCR crosslinking, co-engagement of BCR with IL-21 and CD40
ligation not only inhibits cell death, but augments expansion,
CSR, plasma cell differentiation, and Ig production. Speciﬁcally,
cord blood B cells switch to IgG3 following IL-21 co-stimulation
whereas peripheral blood or splenic naïve B cells switch to IgG1
and IgG3 (Pene et al., 2004; Ettinger et al., 2005). Additionally,
IL-21 polyclonally activates CD27+ memory B cells resulting in
production of all Ig isotypes (Ettinger et al., 2005). IL-21 is also
capable of stimulating IgA production from naïve cord blood or
total CD19+ peripheral blood derived B cells (Ettinger et al., 2005;
Avery et al., 2008a). IL-21 co-activation was not reported to induce
IgA from total splenic B cells (Pene et al., 2004). Notably, however,
IL-21 co-stimulation with anti-CD40 does not have the capacity
to drive isotype switching to IgE (Pene et al., 2004; Ettinger et al.,
2005). Finally, in addition to synergizing with T cell-derived sig-
nals such as CD40, IL-21 can also combine with CpG-induced
TLR-9 signals to promote Ig secretion by peripheral blood B cells
(Massonnet et al., 2009).
High afﬁnity antibodies are often generated by GC-resident
B cells. IL-21 also potently drives plasma cell differentiation and
antibody production from human splenic GC B cells, inducing
production of IgM, IgG, and IgA antibodies (Bryant et al., 2007).
While IL-10 was previously believed to be the critical B cell dif-
ferentiation factor, IL-21 co-stimulation with CD40 engagement
results in the generation of ∼20-fold more Ig secreting cells than
does the combination of CD40 ligation and IL-10 from splenic GC
or blood B cells (Ettinger et al., 2005; Bryant et al., 2007).
Within the splenic microenvironment of the GC, B cells inter-
act with a several cell types but the hallmark of humoral immune
responses is mediated by B cell/T cell interactions, in which both
cell bound receptor/ligand interactions as well as T cell-derived
cytokines play a vital role (Jelinek and Lipsky, 1985). The above
studies have demonstrated that puriﬁed recombinant IL-21 co-
stimulated with anti-CD40 or CD40L-expressing cells can mimic
T cell dependent B cell responses. However, themilieu of cytokines
and co-receptor engagement that follows T cell activation is difﬁ-
cult to recapitulate using recombinant proteins. The critical role
of IL-21 in direct T cell-driven B cell responses was demonstrated
in ex vivo co-culture systems in which T cells are polyclonally
activated (Bryant et al., 2007; Kuchen et al., 2007). We found
that blockade of endogenously produced IL-21 following CD4+
T cell activation was sufﬁcient to signiﬁcantly inhibit B cell expan-
sion,plasma cell differentiation,and antibodyproduction (Kuchen
et al., 2007). Blockade of other cytokines, speciﬁcally, IL-2, IL-4,
or IL-10 did not have the ability to reduce IgG production, how-
ever, anti-IL-4 in combination with anti-CD40L did lessen plasma
cell differentiation. Inhibition of other individual cytokines was
found to diminish IgMproduction albeit to a lesser extent than did
blockade of IL-21 (Kuchen et al., 2007). Importantly, in co-culture
assays using naïve or memory B cells stimulated with activated T
cells, IL-21R-Fc inhibited IgM production from naïve B cells and
IgG production from both naïve and memory B cells, while it had
much less impact on IgM production from pre-switched memory
B cells (Kuchen et al., 2007). Although IL-21 is able to co-stimulate
plasma cell differentiation of pre-switched splenic memory B cells,
post-switched B cells are more sensitive to IL-21 activity (Bryant
et al., 2007; Kuchen et al., 2007). The above ﬁndings support a
mechanismwhereby IL-21 co-stimulation is critical for plasma cell
differentiation of naïve B cells and also plays an important role in
plasma cell differentiation of post-switched memory B cells. IgM
production from pre-switched memory B cells, however, is con-
trolled by many cytokines, including IL-21, as well as additional
factors such as TLR ligands (Bernasconi et al., 2002).
IL-21 can be stimulatory or inhibitory depending on the con-
text in which the IL-21 signal is delivered. Several studies have
demonstrated that the effect of IL-21 is modulated by other
cytokines. Importantly, the two γc cytokines, IL-4 and IL-21, have
both synergistic and opposing activity. One of the ﬁrst studies
to demonstrate this showed that IL-21 inhibits B cell expansion
induced by IL-4 and BCR ligation (Parrish-Novak et al., 2000). IL-
21 does, however, have the ability to greatly enhance IL-4 induced
IgE production when CD40 molecules are co-engaged (Pene et al.,
2004; Wood et al., 2004; Avery et al., 2008b). Other reports sug-
gest that IFNγ production by T cells and NK cells as well as
polymorphisms in the IL-21R inhibit IL-21’s capacity to promote
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IgE in the context of IL-4 stimulation (Pene et al., 2006). The
potential of these two γc cytokines, however, to synergize, is lim-
ited to IgE.Wehave reported that IL-4 greatly inhibits IL-21-driven
plasma cell differentiation and IgG production, especially when
BCR is co-engaged with CD40 ligation or superantigen (Ettinger
et al., 2005). Down regulation of AID and BLIMP-1 appears to be
the mechanism by which IL-4 limits IL-21activity (Ettinger et al.,
2005). Avery et al. (2008a) reported that while IL-4 inhibits IL-
21 and CD40L-induced switching to IgA and IgG3, it increases
switching to IgG1. Cumulatively, these data suggest a complex,
dynamic relationship between IL-21 and IL-4 in driving B cell
responsiveness.
In addition to expansion and differentiation, IL-21 also inﬂu-
ences B cell survival. In contrast to its ability to synergize with
anti-CD40 to induce B cell proliferation and differentiation, IL-
21 triggers cell death when BCR is ligated (Ettinger et al., 2005,
2008b). This induction of cell death is preceded by activation and
several rounds of proliferation, suggesting that IL-21 is inducing
an activation-induced type of cell death which can be reversed by
addition of either anti-CD40 or IL-4 (Ettinger et al., 2005, 2008b).
IL-21 also directly triggers cell death of B cell chronic lymphocytic
leukemia (CLL) cells, the most common type of adult leukemia,
irrespective of whether CD40,BCR,or BAFF receptor (BAFFR) are
co-engaged (de Totero et al., 2006; Jahrsdorfer et al., 2006; Ettinger
et al., 2008b).
This autoregulatory function of IL-21 on B cell survival in both
malignant CLL and non-malignant primary B cells was recently
explained by the observation that IL-21 has the ability to induce
granzyme B (GzmB) resulting in the differentiation of cytolytic
B cells (Jahrsdorfer et al., 2006; Hagn et al., 2009). Treatment
of CLL cells with IL-21 and CpG leads to apoptosis of both the
GzmB producing cells themselves as well as bystander cells (Jahrs-
dorfer et al., 2006). Induction of GzmB is more robust in naïve
compared to memory B cells and is greatly augmented by BCR lig-
ation (Hagn et al., 2010, 2011). Importantly, CD40 signals inhibit
IL-21 induced GzmB production thereby shifting B cell differ-
entiation away from cytotoxicity and toward a plasma cell fate
(Hagn et al., 2011). These data reﬂect the potential of IL-21 to
inﬂuence B cell mediated immune responses in multiple ways.
Early in the response to an infection when pathogens may engage
the BCR in the absence of direct T cell help, IL-21, produced by
bystander T cells, directs B cells to produce GzmB and kill infected
cells. However, later in the response as direct T cell help becomes
available, IL-21 synergizes with CD40L to promote the differenti-
ation of plasma cells which can secrete antibodies directed against
extracellular pathogens.
Cumulatively, these data suggest a model in which IL-21 plays a
critical role in B cell fate decisions. IL-21 serves as a stimulator of
B cell responses when delivered in the context of direct T cell help.
Alternatively, IL-21 in combination with BCR ligation induces cell
death in the absence of cognate T cell help. This function of IL-21
is a potential mechanism whereby autoreactive B cells are kept in
check when the BCR is crosslinked by auto-antigen. However, in
the presence of autoreactive T cells capable of delivering contact-
dependent help in the context of CD40L, IL-21’s death signal
is converted to one which promotes plasma cell differentiation
and ultimately production of pathogenic autoantibodies. These
data along with the observations that IL-21 levels are elevated in
the serum of lupus patients and polymorphisms in the IL-21R
confer risk for systemic lupus erythematosus (SLE) suggest that
targeting the IL-21 pathway may have therapeutic beneﬁts in set-
tings of autoimmunity (Ettinger et al., 2008a,b; Webb et al., 2009;
Wong et al., 2010). Two clinical trials are/were ongoing utiliz-
ing IL-21/IL-21R blockade in normal and autoimmune individual
(NovoNordisk, 2010; Pﬁzer, 2010).
IMPAIRED B CELL MEMORY IN HUMANS WITH DEFECTIVE
IL-21 SIGNALING PATHWAYS
Binding of IL-21 to its receptor activates several members of
the Jak–STAT pathway, including Jak1, Jak3, STAT1, STAT3, and
STAT5. In resting human B cells, activation of STAT3 is most
prominent in response to IL-21 (Habib et al., 2002; Diehl et al.,
2008). Importantly, STAT3 appears critical for IL-21’s role in dri-
ving plasma cell differentiation, as expression of a constitutively
active STAT3 in human B cells was sufﬁcient to induce BLIMP-1
upregulation and antibody production (Diehl et al., 2008).
Additional support for the critical role of STAT3 downstream
of IL-21 comes from studies of patients with STAT3 mutations.
Ex vivo studies with B cells from these individuals reveal that
the synergistic effect of IL-21 and IL-4 on IgE production was
lost in patients with STAT3 mutations (Avery et al., 2008b). More
in depth analysis of these patients revealed reduced frequencies
of circulating memory B cells compared to healthy donors or
patients with STAT1 mutations (Avery et al., 2010). Levels of cir-
culating anti-tetanus IgG were found to be reduced in STAT3
mutant patients and in vitro recall experiments demonstrated
that both the overall frequency and afﬁnity of antigen speciﬁc
B cells was also lower in these individuals. Finally, mutations
in STAT3 largely impaired IL-21-mediated B cell expansion and
plasma cell differentiation (Avery et al., 2010). Interestingly, how-
ever, while the overall number of antibody producing cells was
reduced following stimulation with IL-21 and CD40L, the rela-
tive proportion of STAT3 mutant B cells that expressed IgG1 was
comparable to healthy controls, demonstrating that while plasma
cell differentiation is diminished these cells are still capable of
CSR. While STAT3 mutant B cells fail to upregulate BLIMP-1 in
response to IL-21 and CD40L, upregulation of AID was unaf-
fected by this mutation. These data suggest that IL-21-mediated
induction of AID and class switching is STAT3-independent,
while STAT3 is critical for IL-21-induced B cell expansion, dif-
ferentiation, and/or survival. Together, the above data deﬁne
a role for IL-21 in the generation and maintenance of B cell
memory.
BAFF: TNF FAMILY CYTOKINE WITH COMPLEX BINDING
PARTNERS
Another critical factor in promoting B cell responses is BAFF/BLys
(B cell activating factor). BAFF is a member of the TNF family
of cytokines and exists as either a membrane bound or soluble
form. Initial descriptions suggested that BAFF expression was
limited to lymphoid tissue and was produced by cells of the
myeloid lineage (Moore et al., 1999; Schneider et al., 1999). In
particular, BAFF secretion was detected in dendritic cells and
in cultures of monocytes stimulated with IFNγ (Moore et al.,
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1999). Additional stimuli, such as LPS and IFNα, elicited pro-
duction of both membrane and soluble BAFF by monocytes,
while IFNα potently stimulates BAFF production by dendritic
cells (Litinskiy et al., 2002). More recent studies show however,
that a number of additional cell types, including activated T and
B cells, epithelial cells, neutrophils, and astrocytes, are also capa-
ble of producing BAFF (Scapini et al., 2003; Krumbholz et al.,
2005).
BAFF binds to three different cell surface receptors, BAFFR, B
cell maturation protein A (BCMA), and transmembrane activator
and CAML interactor (TACI), listed in order of afﬁnity for BAFF
(Gross et al., 2000; Thompson et al., 2000, 2001). Much work has
been done to deﬁne the expression pattern of these receptors on
various B cell subsets. BAFFR is the most widely expressed of the
BAFFRs. Speciﬁcally, BAFFR is found on all peripheral blood B
cells, as well as naïve, memory, and marginal zone (MZ) splenic
B cells and both naïve and memory tonsillar B cells (Ng et al.,
2004; Zhang et al., 2005; Darce et al., 2007b; Ettinger et al., 2007).
Tonsil GC B cells also express BAFFR, albeit at lower densities than
the other tonsillar B cell subpopulations (Ng et al., 2004). Bone
marrow resident CD138+ plasma cells, however, lack expression
of BAFFR (Darce et al., 2007b).
The receptors TACI and BCMA, on the other hand, are upreg-
ulated with differentiation. Whereas naïve B cells do not express
TACI and BCMA, TACI upregulation closely follows that of the
memory B cell marker CD27 (Darce et al., 2007b), and remains
expressed on plasma cells. TACI is also expressed on splenic mem-
ory and MZ B cells and to a much lesser extent on follicular B
cells (Ettinger et al., 2007). BCMA is found upregulated on ton-
sillar GC B cells and is expressed on plasma blasts/plasma cells
at high densities (Ng et al., 2004; Zhang et al., 2005). However
naïve and memory B cells as well as splenic MZ B cells do not
appear to express BCMA (Darce et al., 2007b; Ettinger et al.,
2007).
An additional level of complexity in the regulation of BAFFR
expression involves changes in receptor expression with activa-
tion. Naïve B cells upregulate TACI following activation with
various stimuli including CpG alone or BCR ligation in com-
bination with CD40 ligation and cytokine signals such as IL-
21 and IL-10 (Darce et al., 2007b). We have shown that acti-
vation/differentiation of peripheral blood B cells with a com-
bination of IL-21, anti-CD40, and anti-IgM results in signiﬁ-
cant upregulation of BCMA on the IgD–CD38++ plasma cells
which develop in these cultures (Ettinger et al., 2005). Modu-
lation of the three BAFFRs following activation has also been
reported in that CD40L/IL-2/IL-10 stimulated B cells were shown
to downregulate BAFFR while upregulating TACI on speciﬁc B
cell subpopulations (Avery et al., 2003). Moreover, in this sys-
tem, upregulation of BCMA was also noted, but it followed after
many rounds of cell division (Avery et al., 2003). Likewise, B
cells activated with the combination of CpG/IL-2/IL-15 down-
regulate BAFFR with concurrent upregulation of BCMA on the
memory B cell compartment (Darce et al., 2007b). These stud-
ies demonstrate the complex nature of BAFF signaling in B
cells and suggest that this pathway is involved in regulating the
response of both resting and activated B cells at several stages of
differentiation.
BAFF REGULATES HUMAN B CELL SURVIVAL, GROWTH, AND
ANTIBODY PRODUCTION
Early studies demonstrated that BAFF, in either membrane bound
or soluble form, can combine with BCR ligation to stimulate
the growth of B cells derived from peripheral blood or tonsil
(Moore et al., 1999; Schneider et al., 1999). BAFF likely plays a
critical role in regulating B cell expansion in vivo as blockade of
BAFF inhibits both macrophage- and dendritic cell-driven B cell
expansion in vitro (Craxton et al., 2003).
BAFF also controls B cell homeostasis by regulating B cell
survival. BAFF alone promotes the survival of human splenic
B cells, and in particular memory B cells are most sensitive to
the anti-apoptotic effects of BAFF (Avery et al., 2003). In vitro,
BAFF has only a modest effect on the survival of naïve B cells
and does not regulate the survival of circulating human tran-
sitional B cells (Avery et al., 2003; Sims et al., 2005). The pro-
survival effect of BAFF on memory B cells is independent of an
effect on proliferation as BAFF alone does not induce memory
B cells to undergo cell division. The effect of BAFF in mouse
models is quite distinct from human ex vivo studies, as sev-
eral reports have demonstrated that murine memory B cells are
BAFF-independent (Benson et al., 2008; Scholz et al., 2008). In
contrast to mouse studies, the mechanism whereby BAFF regu-
lates human B cell survival does not involve modulation of the
pro-apoptotic factor Bim (Craxton et al., 2003; Ettinger et al.,
2007).
In addition to promoting the survival of resting human mem-
ory cells, BAFF also increases the survival CD38+ plasmablasts.
BAFF and CD40L appear to target distinct memory B subpopula-
tions in this regard as CD40L stimulation preferentially increases
the survival, but not proliferation of CD38− B cell blasts (Avery
et al., 2003). Despite its pro-survival effects, however, BAFF is
unable to protect naïve B cells against cell death induced by the
combination of IL-21 and BCR signaling (Ettinger et al., 2007,
2008b).
An in vivo correlation between BAFF levels and B cell numbers
was demonstrated in studies of patients receiving B cell depletion
therapy. Following B cell depletion in patients with rheumatoid
arthritis (RA), for example, serum BAFF levels rise signiﬁcantly
and remain elevated for varying periods of time (Cambridge et al.,
2006). Importantly, decreased BAFF levels were then associated
with the reemergence of B cells in the periphery. Mechanistically,
increased BAFF protein levels likely arise from a decreased pool
of the BAFFRs following B cell depletion. Additionally, however,
BAFF mRNA levels are also increased following B cell depletion,
suggesting transcriptional control of BAFF is modulated by loss of
B cells (Lavie et al., 2007). Moreover, patients with elevated base-
line BAFF levels have shorter clinical responses to B cell depletion
therapy. More speciﬁcally, there was a positive associate between
patients with quantiﬁable pre-B cell depletion therapy BAFF lev-
els and early ﬂares following B cell depletion. These observations
may suggest that elevatedBAFF levels inﬂuence B cell repopulation
following depletion (Cambridge et al., 2008).
In addition to regulating survival, BAFF also works in concert
with B cell tropic cytokines to induce AID and CSR and to pro-
mote plasma cell differentiation. We have noted minimal effect on
AID, BLIMP-1, CSR, and plasma cell differentiation when BAFF
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is added alone to cultures of puriﬁed human naïve or memory B
cells (Ettinger et al., 2007). However, BAFF synergizes with IL-10
or TGFβ to induce CSR of IgD+ peripheral blood B cells from
Cμ to Cγ or Cα or with IL-4 to induce switching to Cε (Litinskiy
et al., 2002). BAFF used with IL-4 up-regulates IgG and IgA on
the cell surface, however, BCR crosslinking is required for secre-
tion of antibodies (Litinskiy et al., 2002). Importantly, co-culture
of BCR-activated peripheral blood B cells with IFNα-activated
dendritic cells induced plasma cell differentiation and the produc-
tion of IgA and IgG antibodies, which was largely inhibited by
BAFF blockade (Litinskiy et al., 2002). More recent studies sug-
gest that BAFF can synergize with IL-17 to promote the survival
of naïve and memory B cells and in combination with anti-CD40
and anti-IgM, BAFF and IL-17 can substitute for TLR signals to
drive B cell expansion and plasma cell differentiation (Doreau
et al., 2009). IL-17 and BAFF in combination with CD40 and BCR
signaling induces production of all Ig isotypes in vitro, however,
IgM is the dominant isotype detected in these cultures. Both BAFF
and IL-17 levels are elevated in SLE patients, suggesting these two
cytokines may promote the survival and activation of autoreac-
tive B cells in vivo in settings of autoimmunity (Doreau et al.,
2009).
BAFF also has the capacity to impact Ig production from
CD38+, but not CD38−, activated memory B cells. BAFF stim-
ulation in combination with IL-2 and IL-10 globally augmented
the generation of Ig producing cells from the activated memory B
cell pool, with the most pronounced effect on cells producing IgA
(Avery et al., 2003).
BAFF, however, does not always serve as a positive regulator
of B cell activation. In contrast to its ability to stimulate pro-
liferation and Ig production in combination with BCR ligation
and cytokines, BAFF inhibits differentiation and Ig secretion from
CpG-stimulated cells (Darce et al., 2007a). Importantly, when
compared to IL-21 stimulation, BAFF alone or in combination
with anti-CD40 with or without anti-IgM, had minimal ability to
induce plasma cell differentiation or IgG production from total
splenic B cells (Ettinger et al., 2007).
Finally, BAFF also has the ability to inﬂuence the migratory
response of B cells, as BAFF selectively synergizes with CXCL13 to
enhance the chemotactic response of human tonsillar memory B
cells (Badr et al., 2008). The synergy of BAFF and CXCL13 on B
cell chemotaxis implies that BAFF may inﬂuence the formation of
B cell areas and GCs in both lymphoid and non-lymphoid areas.
BAFF BLOCKADE AS A TREATMENT FOR AUTOIMMUNE
DISEASE
The ability of BAFF in combination with B cell tropic factors to
stimulate the growth of B cells and to promote memory B cell
survival, CSR, and antibody production suggest that BAFF would
be an excellent target for neutralization in settings of autoim-
munity where pathogenic autoantibody production contributes
to disease progression. Circulating BAFF levels are elevated in a
number of autoimmune diseases including SLE, RA, and Sjogren’s
syndrome. Moreover, in lupus patients BAFF levels correlate with
disease activity (Cheema et al., 2001; Groom et al., 2002; Becker-
Merok et al., 2006). To date BAFF inhibitors have been tested in
clinical trials for patients with SLE, RA, and multiple sclerosis.
Atacicept/TACI-Ig, which inhibits both BAFF and its homolog
APRIL (a proliferation inducing ligand), partially reduces B cell
numbers in patients with mild to moderate SLE (Dall’Era et al.,
2007). Patients receiving repeat dosing of the drug developed
an initial transient increase of total B cells followed by a sus-
tained reduction of 45–60% of total B cell numbers relative
to baseline. This reduction of B cells correlated with decreased
circulating IgM, IgG, and IgA levels, suggesting that differenti-
ation and/or survival of plasma cells was being affected. The
most dramatic effect was observed on IgM titers which were
reduced nearly 50% compared to baseline in patients receiv-
ing repeated doses (Dall’Era et al., 2007). Similarly, in a trial
with RA patients, repeat dosing of atacicept reduced IgG, IgA,
and IgM levels by 21, 37, and 54%, respectively (Tak et al.,
2008). Importantly, a decrease in rheumatoid factor antibody
titers was also noted in treated patients compared to placebo
controls.
Within the last year, a BAFF-neutralizing monoclonal antibody,
belimumab (Benlysta®), received FDA approval as the ﬁrst new
therapeutic to treat SLE in over 50 years. In a Phase II clinical
trial with SLE patients, belimumab, like atacicept, reduced overall
circulating B cell numbers (Wallace et al., 2009). Additionally, cir-
culating antibodies of all Ig isotypes were reduced by belimumab,
including IgE which declined by as much as 34%. Notably, autoan-
tibodies such as anti-dsDNA were also reduced. Treatment with
belimumab led to undetectable anti-dsDNA IgG titers in 15% of
patients compared to 3% of patients in the placebo group. In this
study,however, therewere no signiﬁcant changes in disease activity
at the study endpoint (Wallace et al., 2009). A follow-up Phase III
study was conducted of longer duration and employed different
endpoint criteria. This study showed that belimumab in combi-
nation with standard of care resulted in a modest but signiﬁcant
clinical improvement compared to placebo (Navarra et al., 2011).
Surprisingly, in contrast to what is observed in vitro where
memory B cells appear to be highly sensitive to BAFF, clin-
ical trials have demonstrated that it is naïve and transitional
B cells which are particularly susceptible to BAFF inhibition
in vivo (Jacobi et al., 2010). Numbers of transitional and naïve
B cells were signiﬁcantly decreased at day 84 following beli-
mumab treatment, and continued to decline up to day 532,
reaching decreases of 88 and 75%, respectively (Jacobi et al.,
2010). On the other hand, at an early time point (day 84) num-
bers of memory B cells were actually increased. This increase in
memory B cell number was transient, yet much longer periods
of time (>1 year) were required to note depletion of memory
B cells and plasma cells following treatment with Belimumab
(Jacobi et al., 2010). The differential effects of BAFF in vitro and
in vivo suggest that while BAFF plays a critical role in regulat-
ing many aspects of B cell function, additional factors, such as
IL-21 may inﬂuence memory B cell survival and differentiation
in vivo.
Clinical trials also demonstrated that BAFF blockade preferen-
tially targets IgM secreting cells, while IgG production is largely
unaffected (Jacobi et al., 2010). The ability of Belimumab to target
IgM may be due to decreases in naïve B cells which are thought
to give rise to short-lived IgM producing plasmablasts, while GC
B cells, which largely give rise to IgG producing cells, may be
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less susceptible. This possibility is supported by observations in
mice which demonstrate that GC formation occurs in a BAFF-
independent manner (Rahman et al., 2003). Additionally, mouse
studies also suggest that APRIL is more prominent than BAFF in
regulating plasma cell survival (Belnoue et al., 2008), which may
contribute to the inability of Belimumab to inhibit IgG levels.
Together, these data suggest that combination therapeutics which
block BAFF along with other B cell tropic factors may be required
to more effectively target memory B cells and long lived plasma
cells.
BAFF AND IL-21 SYNERGIZE TO STIMULATE HUMAN B CELL
MEMORY
Maintenance of serologic memory requires the survival and dif-
ferentiation of memory B cells, both of which are inﬂuenced
by IL-21 and BAFF. Memory B cells are located in several com-
partments, including blood and lymphoid tissue such as lymph
nodes and spleen. Unlike mice, the human spleen contains spe-
cialized IgD+ and IgD− memory B cells located in the MZ that
are somatically mutated (Dunn-Walters et al., 1995; Tangye et al.,
1998; Weller et al., 2005). Previously, we have characterized these
B cells both phenotypically and functionally and termed them
MZ-analog (MZA) B cells as they localize around the follicular
B cell zone in an area similar to that of the mouse MZ (Ettinger
et al., 2007). MZA B cells have a unique phenotype including high
expression levels of CD21,CD27,B220, andCD45RAwhile lacking
expression of CD23, compared with peripheral blood and splenic
non-MZA memory B cell populations that do not express high
densities of CD21, and express lower levels of CD27. MZA B cells
also highly express both BAFFR and TACI (but not BCMA) and
like follicular B cells, survival of MZA B cells is increased by BAFF
(Ettinger et al., 2007).
Not only are MZA B cells distinct in their phenotype, they also
are hyperresponsive to signals that mimic T cell activation. In vitro
activation of sorted human splenic B cell populations revealed that
IgG+ MZA B cells are exquisitely sensitive to IL-21 and anti-CD40
stimulation compared to follicular B cells. Both the extent and rate
of plasma cell differentiation andproductionof IgGantibodieswas
greatly increased over the other splenic naïve and memory B cell
subpopulations (Ettinger et al., 2007).
IgG+ MZA B cells are also unique in respect to signals capable
of driving their differentiation into plasma cells. In most cases,
when TLR ligands are not engaged, plasma cell differentiation
requires a combination of B cell tropic cytokines, CD40 stimu-
lation, and/or BCR ligation. However, we found that IgG+ MZA
B cells are capable of being activated in an antigen-independent,
bystander fashion by a combination of T cell- and DC-derived
soluble mediators. Speciﬁcally, sorted, puriﬁed IgG+ MZA B cells
have the ability to upregulate BLIMP-1, but not AID, following
exposure to IL-21 alone. Notably, stimulation with both BAFF and
IL-21 results in rapid plasma cell differentiation and production
of IgG antibodies. Moreover, the combination of IL-2 and IL-10
which induces plasma cell differentiationof memory splenicB cells
co-stimulated with CD40L (Tangye et al., 1998), was signiﬁcantly
less potent at inducing plasma cell differentiation and IgG produc-
tion from CD21hi MZA than the combination of IL-21 and BAFF.
The capacity to differentiate into plasma cells in response to IL-21
FIGURE 1 | Unique and synergistic effects of IL-21 and BAFF on human
B cell subsets.The combination of IL-21 and BCR engagement triggers cell
death in naive B cells. CD40 signals, but not BAFF, reverse this cell death in
naive B cells and combine with IL-21 to induce class switch recombination
(CSR), plasma cell differentiation (PC) and antibody production in all B cell
subsets. Importantly, post-switched MZA B cells represent a unique subset
of cells capable of differentiating and producing Ig in response to IL-21 and
BAFF alone in the absence of CD40 engagement.
and BAFF in the absence of CD40 or BCR ligation was unique to
post-switched MZA, as splenic naïve, memory, or IgG− or IgM+
MZA B cells were unable to respond in this fashion. The ability of
BAFF to serve as a surrogate to CD40 signaling may be explained
by the fact that BAFF and anti-CD40 both share common signal
events via NFκB (Qian et al., 2004; Lin-Lee et al., 2006).
Marginal zone-analog B cells, therefore, represent a population
of memory B cells that have the unique capability of responding in
an antigen-independent manner to cytokines alone. Importantly,
based on their localization in the human spleen in proximity to
both T cells capable of producing IL-21 and dendritic cells capable
of secreting BAFF (Ettinger et al., 2007), these specialized B cells
may very well contribute to the maintenance of serologic memory
through rapid plasma cell differentiation and production of high
afﬁnity IgG antibodies. Previous studies have reported that com-
pared to post-switched GC B cells, pre-switched MZ B cells from
the bloodor spleenof infants have high clonal diversity (Weill et al.,
2009). A better understanding of the repertoire of post-switched
MZA B cells and their autoreactive potential is an area of interest
for future studies.
CONCLUSION
Clearly, IL-21 and BAFF play fundamental roles in regulating vari-
ous aspects of human humoral immuno-responsiveness including
B cell survival, activation, expansion, CSR, plasma cell differ-
entiation, and production of antibodies (Figure 1). As such,
these two very inﬂuential cytokines are attractive targets for the
treatment of autoimmune disease. Although BAFF blockade has
proven clinical activity for the treatment of SLE, dual targeting
of BAFF with other B cell tropic factors, such as IL-21, may pro-
vide additional therapeutic options for this severely debilitating
disease.
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